combi-ad trial: adjuvant dabrafenib plus trametinib in patients with resected stage iii braf v60...
Published 4 years ago • 229 plays • Length 4:45Download video MP4
Download video MP3
Similar videos
-
1:49
combi-ad: dabrafenib plus trametinib in advanced melanoma
-
6:16
dabrafenib plus trametinib for stage iii mutant melanoma
-
2:51
combi-ad: long-term follow-up of dabrafenib and trametinib in braf-mutated melanoma
-
3:06
combi-d: phase 3 trial of dabrafenib plus trametinib in braf v600e/k-mutated melanoma
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
4:12
adjuvant therapy in melanoma: combi-ad trial
-
2:08
phase 3 combi-d trial of dabrafenib plus trametinib in metastatic
-
4:08
updates from combi-ad: dabrafenib and trametinib for melanoma
-
2:12
phase iii combi-d study of dabrafenib and trametinib in patients with melanoma
-
1:08
fda approval of adjuvant dabrafenib/trametinib in braf melanoma
-
1:11
dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
4:17
health related quality of life findings from combi-ad
-
0:53
dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
-
1:17
dr. dummer on combi-ad trial results in braf-mutant melanoma
-
0:56
5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma
-
7:32
continuous vs intermittent dosing of dabrafenib and trametinib in braf mutated melanoma
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
3:02
a new standard for stage 3 braf melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma